Please login to the form below

Not currently logged in
Email:
Password:

Novartis face $590m impairment charges

Novartis will face impairment charges of $590m following the discontinued development of two investigational compounds

Novartis will face total impairment charges of $590m following the discontinued development of the investigational compounds Mycograb (efungumab), an antifungal treatment for invasive candidiasis in adults, and albinterferon alfa-2b, being assessed as a therapy for chronic hepatitis C.

According to the company, the decision to halt the development of the compounds reflected an "enhanced focus on differentiated medicines most likely to address unmet medical needs."

Feedback from regulatory authorities in the EU and US, as well as data from a recent phase II study involving albinterferon alfa-2b, were also said to have contributed towards the choice.

Impairment and related charges for the Swiss company concerning the discontinuation of albinterferon alfa-2b come to $230m, with a further $390m in charges over the decision to halt Mycograb development.

Impairment charges are a reduction in the value of a company based on poor estimates regarding a company's intangible assets.

These charges will be reflected in Novartis' third quarter results.

The company said the charges will be partially offset through the sale of US rights for overactive bladder treatment Enablex (darifenacin) to Warner Chilcott for $400m.

A statement from Novartis said it expects a gain of around $390m to be recorded in the fourth quarter of 2010.

5th October 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics